Accession Number:



Inhibiting Lysine Specific Demethylase 1 Activity as a Potential Therapeutic Treatment for Castration-Resistant Prostate Cancer

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:


Personal Author(s):

Report Date:


Pagination or Media Count:



Reactivation of androgen receptor AR signaling are found in the majority of castration resistant prostate cancer CRPC and CRPC resistant to enzalutamide, indicating a pressing need for further development of novel AR-targeted therapies. Lysine-Specific Demethylase 1LSD1 functions as a transcriptional corepressor through demethylation of histone 3 lysine 4 H3K4 but also has a coactivator function on AR. In this project, we have shown that LSD1 broadly enhances AR chromatin binding and activity by increasing enhancer accessibility prior to androgen stimulation through demethylating the pioneer factor FOXA1 and stabilizing FOXA1 chromatin binding. Moreover, in addition to regulating AR signaling, LSD1 and BRD4 are coenriched at the super-enhancers that are associate with oncogenic transcription factor genes, such as MYC, and regulate their expressions. We are currently testing the combination treatment of LSD1 inhibitor and BET inhibitors in CRPC models. Our findings provide novel therapeutic insights on developing LSD1 inhibitor treatment in CRPC.

Subject Categories:

  • Medicine and Medical Research
  • Anatomy and Physiology
  • Biochemistry

Distribution Statement:

[A, Approved For Public Release]